-col-
avelumab
figitumumab
adecatumumab
tenatumomab
dacetuzumab
tigatuzumab
naptumomab estafenatox
conatumumab
nofetumomab
-got-
inotuzumab
-les-
acrixolimab
duligotuzumab
sibrotuzumab
inotuzumab ozogamicin
pamrevlumab
cixutumumab
onartuzumab
panitumumab
ramucirumab
tisotumab
labetuzumab
-pro-
mapatumumab
patritumab
oleclumab
lexatumumab
dalotuzumab
votumumab
matuzumab
olendalizumab
lintuzumab
-tum-
carlumab
agonistic monoclonal antibody
drozitumab
cantuzumab
samalizumab
-mel-
tremelimumab
lucatumumab
satumomab
etaracizumab
teprotumumab
nacolomab tafenatox
oportuzumab monatox
catumaxomab
alacizumab
cemiplimab
endotrophin
ertumaxomab
muromonab
volociximab
milatuzumab
iratumumab
epichaperome
atezolizumab
nimotuzumab
durvalumab
colitis
apolizumab
amivantamab
ravulizumab
brolucizumab
abagovomab
gevokizumab
tislelizumab
cergutuzumab
olaratumab
pidilizumab
-toxa-
pertuzumab
relatlimab
siltuximab
folliculin
colonocyte
antimonoclonal
robatumumab
abituzumab
inflammatory bowel disease
carcinosarcoma
oncotropic
altumomab
zalutumumab
arcitumomab
colosphere
oncoimmunology
besilesomab
hexastatin
sigmoid flexure
antinucleosome
sigmoideum
detumomab
ensituximab
rectosigmoiditis
malignin
taplitumomab